March 12th 2021
A historical review of treatment advances in relapsed/refractory multiple myeloma and criteria used to define relapsed or refractory disease.
Factors that influence treatment selection for relapsed or refractory multiple myeloma, and suggestions to help streamline decision making and address limitations associated with current treatment pathways.
Healthcare stakeholders comment on current practices managing patients with relapsed/refractory multiple myeloma during the COVID pandemic and discuss their comfort switching patients over from intravenous daratumumab to subcutaneous daratumumab.
Variables considered by healthcare professionals when selecting an appropriate backbone regimen to manage a patient with relapsed or refractory multiple myeloma.
Considerations for treating patients with relapsed/refractory multiple myeloma with elotuzumab, daratumumab, or isatuximab based on more recent clinical trial data and differences between each treatment option.
Best practices for prescribing an immunomodulatory-based therapy or a proteasome inhibitor as treatment for relapsed/refractory multiple myeloma.
March 17th 2021
Recommendations for managing patients who receive belantamab mafodotin, an anti-BCMA therapy, for relapsed/refractory multiple myeloma, with special considerations regarding the ocular health of patients.
Robert Mancini, PharmD, BCOP, FHOPA, of St. Luke’s Cancer Institute: Boise, comments on his experience navigating challenges using belantamab mafodotin, an anti-BCMA therapy, to treat relapsed/refractory multiple myeloma.
March 26th 2021
The importance of coordinated care and proper education to pharmacists on best practices when dispensing anti-BMCA therapy to patients with relapsed/refractory multiple myeloma.
Novel treatment strategies being explored in clinical trials that look exciting in relapsed/refractory multiple myeloma, and implications for using these newer approaches in the future.
